Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

Publikation

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

Wissenschaftlicher Artikel/Review - 01.03.2009

Putzki Norman, Kollia K, Woods S, Igwe E, Diener H C, Limmroth V

Zitation

Putzki N, Kollia K, Woods S, Igwe E, Diener H, Limmroth V. Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis. European journal of neurology : the official journal of the European Federation of Neurological Societies 2009; 16:424-6.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

European journal of neurology : the official journal of the European Federation of Neurological Societies 2009; 16

Veröffentlichungsdatum

01.03.2009

eISSN (Online)

1468-1331

Seiten

424-6

Kurzbeschreibung/Zielsetzung

BACKGROUND: Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon-beta (IFN-beta) or glatiramer acetate (GA). METHOD: Prospective, observational study. RESULTS: We found a reduction of the annualized relapse rate from 2.1 under IFN-beta or GA to 0.2 one year after switching to natalizumab. There were 94% fewer gadolinium enhancing lesions with natalizumab. CONCLUSION: Natalizumab reduced short term clinical and MRI activity in second line therapy and efficacy is comparable to first line therapy as demonstrated in the pivotal trials.